Corgenix Medical Corporation executes technology licensing agreement with Okayama Prefecture Industrial Promotion Foundation

Wed. March 19, 2008; Posted: 06:51 AM

Mar 19, 2008 (M2 EQUITYBITES via COMTEX) -- CONX | news | PowerRating | PR Charts -- Corgenix Medical Corporation (OTCBB: CONX), a developer and marketer of diagnostic test kits, declared on 18 March that the company has signed a worldwide licensing agreement with the Okayama Prefecture Industrial Promotion Foundation, a Japanese government agency promoting research and development among industry, universities and governments.

The new license agreement covers new diagnostic technology for serum amyloid protein (SAP), an important serum bio-marker for cardiovascular inflammation.

The serum amyloid technology was developed by Dr Eiji Matsuura at the University of Okayama Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.

Corgenix, under the terms of the agreement, has the exclusive rights outside of Japan to further develop the serum amyloid technology, including adapting to research and clinical diagnostic products.

Comments on this story may be sent to admin@m2.com

For full details for CONX click here.

More News: Market Updates | Stock Alerts | All Trading News | Stock Index

Archives

Feedback

Email Article Link

Close X

RELATED SITES

Please call 1-213-955-5858 ext. 1

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.